RVMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Revolution Medicines's revenue for the three months ended in Sep. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.74 Mil. Revolution Medicines's Revenue per Share for the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.01.
Warning Sign:
Revolution Medicines Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Revolution Medicines was -98.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -49.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 7 years, Revolution Medicines's highest 3-Year average Revenue per Share Growth Rate was -9.90% per year. The lowest was -49.30% per year. And the median was -22.60% per year.
The historical data trend for Revolution Medicines's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Revenue | Get a 7-Day Free Trial | 50.04 | 42.98 | 29.39 | 35.38 | 11.58 |
Revolution Medicines Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Revenue | Get a 7-Day Free Trial | - | 0.74 | - | - | - |
For the Biotechnology subindustry, Revolution Medicines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revolution Medicines's Revenue distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (NAS:RVMD) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Revolution Medicines's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeff Cislini | officer: General Counsel | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Stephen Michael Kelsey | officer: See Remarks | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Mark A Goldsmith | director, officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Sushil Patel | director | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
Margaret A Horn | officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jack Anders | officer: Chief Financial Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Barbara Weber | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Xiaolin Wang | officer: See Remarks | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Thilo Schroeder | director | C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001 |
Lorence H. Kim | director | C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Flavia Borellini | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Peter Svennilson | director, 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Vincent A. Miller | director | C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 08-08-2024
By Marketwired • 11-06-2024
By Marketwired • 11-05-2024
By GuruFocus News • 11-09-2024
By PRNewswire • 07-08-2024
By GuruFocus News • 11-07-2024
By Marketwired • 12-05-2024
By GuruFocus Research • 06-20-2024
By Marketwired • 10-25-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.